Delivery Order SPE2DB25D3202-SPE2DB25FTBBC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,227.41 to AmerisourceBergen Drug Corp for MYRBETRIQ ER 50 mg tablets (30-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a single transaction under AmerisourceBergen's larger pharmaceutical supply contract. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of MYRBETRIQ ER 50 mg tablets (90-count quantity) valued at $7,075.56. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitive award to the prime contractor. The contract is set to be completed by July 30, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. MYRBETRIQ...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for MYRBETRIQ ER 50 MG tablets (quantity: 90-count supply) with a ceiling value of $3,120.05 under a firm fixed price contract. This is a non-set-aside award issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999.99 billion potential value through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order valued at $4,013.94 to AmerisourceBergen Drug Corp for 90-count tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. Awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, this firm fixed-price contract utilized competitive procedures with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a $7,794.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count unit). The contract utilizes firm fixed-price pricing with an ultimate completion date of July 29, 2025, and represents a non-competitive, non-set-aside award. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $1...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Myrbetriq ER 25 mg tablets (90-count supply) with a ceiling value of $1,023.10. This firm fixed-price delivery order, awarded on July 29, 2025, represents a non-competitive set-aside award and is expected to be completed by July 30, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $28,170.24 by the Defense Logistics Agency (DLA) for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 1, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $38,869.51 delivery order to AmerisourceBergen Drug Corp for 90-count tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. This firm fixed-price, competitively awarded delivery order is scheduled for completion by July 28, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award carries no set-aside designation and represents a routine pharmaceutical procurement through the federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $2,729.22 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (30-count supply). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 1, 2025, and represents a competitively awarded transaction under AmerisourceBergen's broader pharmaceutical supply relationships with the federal government. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $13,463.38 delivery order to AmerisourceBergen Drug Corp for MYRBETRIQ ER 50 MG tablets (90-count) with a completion date of July 31, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The award represents a pharmaceutical supply delivery to support federal medical procurement needs, with performance conducted at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- SPE2DB25D3202Indefinite Delivery Contract
- SPE2DB25D3202-SPE2DB25FTBBCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for MYRBETRIQ ER 25 mg tablets (90-count) valued at $5,569.27 under a firm fixed price contract. This award, issued on July 31, 2025, represents a non-set-aside competitive award with an ultimate completion date of August 1, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. MYRBETRIQ (mirabegron) is a beta-3 agonist medication used to treat overactive bladder, indicating this delivery supports the military healthcare supply chain's pharmaceutical requirements. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December 2026 that provides comprehensive global pharmaceutical support to military healthcare programs. As a major pharmaceutical distributor, AmerisourceBergen serves critical federal medical procurement needs across multiple therapeutic domains, supplying specialty medications, brand-name and generic drugs, vaccines, and related medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates consistent capability to meet competitive procurement requirements across a broad range of medical commodities supporting military personnel and veteran healthcare initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 7/31/25 |